RE-WIRING THE BRAIN

We harness the power of neuroplasticity

Potent, rapid-acting and long-lasting without hallucinations – Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered

Mental disorders are a huge global challenge

970 million people around the world live with a mental disorder. Depression and post traumatic stress alone affect over 300 million people worldwide. Resulting in the unnecessary loss of 500000 lives every year.

Delivering a simple medical solution

Built on the recent groundbreaking scientific findings and already moving into clinical proof with molecular platforms – we are developing a life changing treatment of the highest demand.

Targeted medicine that can result in rapid and long-lasting effect in neuropsychiatric conditions and improve neurodenegenerative conditions such as Alzheimer's and Parkinson's disease.

  1. Casarotto PC, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299-1313

  2. Hesselgrave N, et al. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. PNAS. 2021;118:e2022489118.

  3. Moliner R, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032-1041

  4. Rosenblat JD, et al. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. Am J Psychiatry. 2023;180:395-396

“Kasvu has a proprietary 3D model of the TrkB receptor using AI-powered technology and employs structure-based drug design to identify selective positive allosteric modulators of TrkB. Join us for an exciting journey to deliver a desired treatment for a global market.”

Jami Mandelin, CEO

Breakthrough medical discovery

Improving plasticity and cognitive function, our molecules can be developed into a safe and effective treatment for mental disorders and neurodegenerative diseases.

  • Effective

    Fast-acting medicine with shorter treatment periods

  • Sustainable

    Long-lasting effect without hallucinations

  • Varied

    Suitable for wide range of conditions where neuronal connectivity is altered

Efficient treatment of neuropsychiatric and neurodegenerative diseases supports social economy and well being

  • Personal treatment

    Self-take medication provides simple distribution and usability

  • Industry economy

    Effective treatments with limited side effects reduce the cost and burden on healthcare system

  • Social safety

    Targeted medical solution has no risk of recreational use

Genetic linkage to relevant diseases with over 30 years of basic science and 34,000+ publications

What is the solution?

First and best-in-class neuroplastogens for the treatment of neuropsychiatric and neurodegenerative diseases.

How is it developed?

Proprietary AI-powered supercomputing model of the activated TrkB dimer has allowed the identification of novel small molecule platforms which are being optimised for clinical development.

What does it do?

The molecules engage TrkB and improve neuronal plasticity and cognitive function.

“TrkB has been a practically impossible target for drug development. We have proprietary technology to develop TrkB specific positive allosteric modulators to provide a targeted therapy for brain diseases and help millions of people with neuropsychiatric disorders.”

Rafael Moliner, Principal Scientist, CoFounder

Industry and investment opportunities

Our treatment is solving some of the biggest unmet needs in the society and has the potential to improve the life of millions worldwide. 

Contact our team and join us to deliver solutions for some of the greatest and most urgent medical challenges.